Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2023-10-18 Capital/Financing Update
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a brokered private placement financing by Sona Nanotech Inc. It details the terms of the financing, including the number of units, pricing, warrants, use of proceeds, and the agent involved. There are no financial statements or detailed financial performance data included. The content focuses on capital raising activities and financing structure rather than reporting financial results or management discussion. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 5505 characters, which is sufficient to contain substantive information about the financing but not a full financial report.
2023-10-18 English
News release - English.pdf
Regulatory Filings
2023-10-12 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CFO of Sona Nanotech Inc. regarding the review and fair presentation of interim financial statements and interim MD&A for the period ended July 31, 2023. It is titled 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS' and explicitly states it is a Venture Issuer Basic Certificate. The content is primarily an officer certification letter, not the interim report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3042 characters), and it does not contain actual financial data or substantive financial analysis, only the certification of such filings. Therefore, the correct classification is Regulatory Filings (RNS).
2023-09-28 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form titled 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS' by the CEO of Sona Nanotech Inc. It certifies the review and fair presentation of the interim financial statements and interim MD&A for the period ended July 31, 2023. The document explicitly states it is a certification of interim filings, not the filings themselves. It contains no actual financial data or detailed financial statements, only the CEO's attestation. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR). The document length is short (3037 characters), and it is a certification form rather than a full report or announcement of a report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2023-09-28 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management Discussion and Analysis Nine-months ended July 31, 2023' and contains detailed discussion of company performance, business strategy, forward-looking statements, and operational overview. It references unaudited condensed interim financial statements for the nine-month period and audited financial statements for the prior year. The content includes management's explanation of business trends, risks, and outlook, which is characteristic of a Management Discussion and Analysis (MD&A) report. The document length is substantial (15,000 characters) and contains substantive financial and operational analysis, not merely an announcement or certification. Therefore, it fits the category of Management Reports (MDA).
2023-09-28 English
Interim financial statements/report – English.pdf
Regulatory Filings
2023-09-28 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.